2Morris I,Varughese G,Mattingly P.Colchicine in acute gout[J].Bmj,2003,327(7426):1275-1276.
3Kim K Y,Ralph Schumacher H,Hunsche E,et al.A literature review of the epidemiology and treatment of acute gout[J].Clinical therapeutics,2003,25(6):1593-1617.
4Senna G,BilòM B,Antonicelli L,et al.Tolerability of three selective cyclo-oxygenase-2 inhibitors,meloxicam,celecoxib and rofecoxib in NSAID-sensitive patients[J].Eur Ann Allergy Clin Immunol,2004,36(6):215-218.
5Riendeau D,Percival M D,Brideau C,et al.Etoricoxib(MK-0663):preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2[J].J Pharmacol Exp Ther,2001,296(2):558-566.
6Vane J R,Warner T D.Nomenclature for COX-2 inhibitors[J].The Lancet,2000,356(9239):1373-1374.
7Tausche A K,Richter K,Grssler A,et al.Severe gouty arthritis refractory to anti-inflammatory drugs:treatment with antitumour necrosis factor alpha as a new therapeutic option[J].Ann Rheum Dis,2004,63(10):1351-1352.
8Terkeltaub R.Update on gout:new therapeutic strategies and options[J].Nat Rev Rheumatol,2010,6(1):30-38.
9So A,De Meulemeester M,Pikhlak A,et al.Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis:Results of a multicenter,phase II,dose-ranging study[J].Arthritis Rheum,2010,62(10):3064-3076.
10Schumacher H R,Sundy J S,Terke L R,et al.Placebo controlled study of rilonacept for gout flare prophylaxis during initiation of urate lowering therapy[J].Arthritis Rheum,2009,60(4):410.
